異檸檬酸脫氫酶1(IDH1)重組蛋白
Recombinant Isocitrate Dehydrogenase 1, Soluble (IDH1)
PICD; IDP; Oxalosuccinate decarboxylase; NADP(+)-specific ICDH; Cytosolic NADP-isocitrate dehydrogenase
- 編號(hào)RPH839Hu01
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 來源原核表達(dá)
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測定)
- 亞細(xì)胞定位細(xì)胞質(zhì)
- 預(yù)測分子量30.6kDa
- 實(shí)際分子量30kDa(差異分析請(qǐng)參閱說明書)
- 片段與標(biāo)簽Ala74~Ile333 with N-terminal His Tag
- 緩沖液成份20mM Tris, 150mM NaCl緩沖液(pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300)
- 性狀凍干粉
- 純度> 97%
- 等電點(diǎn)7.2
-
應(yīng)用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白,請(qǐng)參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 1018 ¥ 2544 ¥ 5088 ¥ 15264 ¥ 38160
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
序列
用法
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過一個(gè)月,-80°C不超過12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲(chǔ),損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPH839Hu01 | 異檸檬酸脫氫酶1(IDH1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAH839Hu01 | 異檸檬酸脫氫酶1(IDH1)多克隆抗體 | WB,IHC |
FAH839Hu01 | 抗異檸檬酸脫氫酶1(IDH1)多克隆抗體 | Flow cytometry. |
MAH839Hu22 | 異檸檬酸脫氫酶1(IDH1)單克隆抗體 | WB; IHC |
MAH839Hu23 | 異檸檬酸脫氫酶1(IDH1)單克隆抗體 | WB; IHC; ICC; IP. |
MAH839Hu25 | 異檸檬酸脫氫酶1(IDH1)單克隆抗體 | WB; IHC; ICC; IP. |
MAH839Hu27 | 異檸檬酸脫氫酶1(IDH1)單克隆抗體 | WB; IHC; ICC; IP. |
MAH839Hu29 | 異檸檬酸脫氫酶1(IDH1)單克隆抗體 | WB; IHC; ICC; IP. |
MAH839Hu24 | 異檸檬酸脫氫酶1(IDH1)單克隆抗體 | WB; IHC |
MAH839Hu26 | 異檸檬酸脫氫酶1(IDH1)單克隆抗體 | WB; IHC |
MAH839Hu21 | 異檸檬酸脫氫酶1(IDH1)單克隆抗體 | WB; IHC; ICC; IP. |
RAH839Hu21 | 異檸檬酸脫氫酶1(IDH1)重組抗體 | WB; IFC; IHC; IP. |
FAH839Hu02 | 抗異檸檬酸脫氫酶1(IDH1)單克隆抗體 | Flow cytometry. |
FAH839Hu04 | 抗異檸檬酸脫氫酶1(IDH1)單克隆抗體 | Flow cytometry. |
FAH839Hu06 | 抗異檸檬酸脫氫酶1(IDH1)單克隆抗體 | Flow cytometry. |
FAH839Hu08 | 抗異檸檬酸脫氫酶1(IDH1)單克隆抗體 | Flow cytometry. |
LAH839Hu76 | 異檸檬酸脫氫酶1(IDH1)單克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
IEH839Hu | 異檸檬酸脫氫酶1(IDH1)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,快捷型) | Enzyme-linked immunosorbent assay for Antigen Detection. |
SEH839Hu | 異檸檬酸脫氫酶1(IDH1)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
SCH839Hu | 異檸檬酸脫氫酶1(IDH1)檢測試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
LMH839Hu | 異檸檬酸脫氫酶1(IDH1)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
PSH839Hu01 | 異檸檬酸脫氫酶1(IDH1)抗體對(duì) | ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays. |
KSH839Hu01 | 異檸檬酸脫氫酶1(IDH1)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Molecular & Cellular Proteomics | Identification of IDH1 as a Potential Diagnostic and Prognostic Biomarker for Non-small-cell Lung Cancer by Proteomic Analysis [Mcponline: 008821] |
Molecular & Cellular Proteomics | Identification of Isocitrate Dehydrogenase 1 as a Potential Diagnostic and Prognostic Biomarker for Non-small Cell Lung Cancer by Proteomic Analysis [Pubmed: 22064513] |
Clinical Cancer Research | Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer [Pubmed: 24046070] |
Onco Targets Ther | The effects of PGC-1α on the proliferation and energy metabolism of malignant endometrial cancer cells [PubMed: 25914546] |
Oncogene | Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism [Pubmed:29921847] |
Molecular Oncology | IDH 2 is a novel diagnostic and prognostic serum biomarker for non‐small‐cell lung cancer [Pubmed:29465809] |
Cancers | Serological Biomarkers for Early Detection of Hepatocellular Carcinoma: A Focus on Autoantibodies against Tumor-Associated Antigens Encoded by Cancer Driver … [Pubmed: 32443439] |
International Journal of Cancer | Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer [Pubmed:35689436] |
留言咨詢